Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab
Copyright © 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a substantial burden on patients' quality of life and impaired sleep quality. The most common CRSwNP endotype is characterized by type 2 inflammation, with enhanced production of interleukin (IL)-4, IL-5, and IL-13. Dupilumab is a monoclonal antibody against IL-4 receptor-α, which inhibits both IL-4 and IL-13 signaling, and was recently approved for treatment of CRSwNP.
OBJECTIVE: We investigated the effect of dupilumab on the sleep quality of patients with CRSwNP in a real-life setting.
METHODS: Patients were evaluated at baseline and after 1 and 3 months of dupilumab treatment by means of the Epworth sleepiness scale (ESS), insomnia severity index (ISI), Pittsburgh sleep quality index (PSQI), and sinonasal outcome test 22 (SNOT-22) sleep domain.
RESULTS: A total of 29 consecutive patients were enrolled, and their baseline sleep quality assessment were as follows: ESS of 7.9 (± 4.5); ISI of 13.1 (± 6.2); PSQI of 9.2 (± 3.7); and SNOT-22 sleep domain of 12.1 (± 4.2). Excessive daily sleepiness, insomnia, and globally impaired sleep quality were present in 24.1%, 79.3%, and 93.1% respectively. Treatment with dupilumab was associated with significant improvement in ESS, ISI, PSQI, and SNOT-22 sleep domain with concomitant reduction of the proportion of patients with insomnia and globally impaired sleep quality.
CONCLUSION: CRSwNP was associated with a significant impact on global sleep quality, in particular, insomnia, and treatment with dupilumab induced a rapid improvement (after 1 single month of treatment) in all the sleep quality parameters, suggesting that sleep disturbances should be more carefully evaluated as an additional outcome in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology - 132(2023), 1 vom: 01. Jan., Seite 69-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferri, Sebastian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 22.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anai.2023.08.594 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361500580 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361500580 | ||
| 003 | DE-627 | ||
| 005 | 20231227135852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anai.2023.08.594 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1235.xml |
| 035 | |a (DE-627)NLM361500580 | ||
| 035 | |a (NLM)37652235 | ||
| 035 | |a (PII)S1081-1206(23)00631-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferri, Sebastian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 22.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a substantial burden on patients' quality of life and impaired sleep quality. The most common CRSwNP endotype is characterized by type 2 inflammation, with enhanced production of interleukin (IL)-4, IL-5, and IL-13. Dupilumab is a monoclonal antibody against IL-4 receptor-α, which inhibits both IL-4 and IL-13 signaling, and was recently approved for treatment of CRSwNP | ||
| 520 | |a OBJECTIVE: We investigated the effect of dupilumab on the sleep quality of patients with CRSwNP in a real-life setting | ||
| 520 | |a METHODS: Patients were evaluated at baseline and after 1 and 3 months of dupilumab treatment by means of the Epworth sleepiness scale (ESS), insomnia severity index (ISI), Pittsburgh sleep quality index (PSQI), and sinonasal outcome test 22 (SNOT-22) sleep domain | ||
| 520 | |a RESULTS: A total of 29 consecutive patients were enrolled, and their baseline sleep quality assessment were as follows: ESS of 7.9 (± 4.5); ISI of 13.1 (± 6.2); PSQI of 9.2 (± 3.7); and SNOT-22 sleep domain of 12.1 (± 4.2). Excessive daily sleepiness, insomnia, and globally impaired sleep quality were present in 24.1%, 79.3%, and 93.1% respectively. Treatment with dupilumab was associated with significant improvement in ESS, ISI, PSQI, and SNOT-22 sleep domain with concomitant reduction of the proportion of patients with insomnia and globally impaired sleep quality | ||
| 520 | |a CONCLUSION: CRSwNP was associated with a significant impact on global sleep quality, in particular, insomnia, and treatment with dupilumab induced a rapid improvement (after 1 single month of treatment) in all the sleep quality parameters, suggesting that sleep disturbances should be more carefully evaluated as an additional outcome in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 650 | 7 | |a Interleukin-13 |2 NLM | |
| 700 | 1 | |a Montagna, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Casini, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Malvezzi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Pirola, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Racca, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Messina, Maria Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Puggioni, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Nappi, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzo, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Del Moro, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Mercante, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Spriano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Canonica, Giorgio Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Paoletti, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Heffler, Enrico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology |d 1995 |g 132(2023), 1 vom: 01. Jan., Seite 69-75 |w (DE-627)NLM075127695 |x 1534-4436 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:69-75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anai.2023.08.594 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2023 |e 1 |b 01 |c 01 |h 69-75 | ||